Fritextsökning
Artiklar per år
Innehållstyper
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward
-
Karolinska nionde bästa sjukhuset i världen i ny rankning
Återigen rankar Newsweek de bästa sjukhusen i världen. I år har de listat de sjukhus som är bäst på att använda ny teknik. Karolinska universitetssjukhuset utmärker sig inom artificiell intelligens och hamnar på plats 9 av 300 sjukhus.
-
Life Science-podden: The perfect moment for an IPO
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
-
Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”
For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.
-
Johan Dahlin går till BMS
Från kommunikationschef på Janssen Sverige till Associate Director Corporate Affairs på Bristol Myers Squibb – den 3 oktober stiger Johan Dahlin in på BMS:s kontor i Solna.
-
Konferens om läkemedelsformuleringar samlar branschen i Köpenhamn
Idag pågår den tionde upplagan av New Updates in Drug Formulation & Bioavailability 2022 i Köpenhamn.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Genes from Neanderthals can affect the correct drug dosage
A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for the drug doses they should take.
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
Stort engagemang på möte om medicinteknik: "Vi vet att lösningarna finns"
Hur ska alla innovativa medicintekniska lösningar inom diagnostik och behandling kunna nå patienten – utan att snubbla på alla juridiska, tekniska och formella hinder på vägen? Det var ämnet för ett välbesökt event i Göteborg på onsdagen.
-
Sweden is heavily criticised for not ordering Covid vaccine
Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.
-
Svensk-amerikanskt biotech-företag flyttar in i Forskaren
ITB Med etablerar sitt svenska kontor och laboratorium i Hagastaden. Under sommaren 2024 flyttar det biofarmaceutiska företaget in i Forskaren, på en 500 kvadratmeter stor yta.
-
Newly discovered gene variant linked to protection against abdominal obesity
American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the discovery will lead to new treatments that can help reduce the risk of type 2 diabetes
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which
-
Läkare vid Karolinska presenterar rön som kan ge bättre behandling av leukemi
Forskare vid Karolinska universitetssjukhuset har hittat en metod för mer effektiv behandling av aggressiv blodcancer, enligt en ny studie.
-
Danska Evaxion Biotech får ny svensk vd
Lars Staal Wegner har meddelat att han kommer att avgå som vd för det danska biotech-bolaget Evaxion. Ny vd är redan klar – det blir Per Norlén som tar över tjänsten.
-
Konkurrenskraft, cancervård och MDR – läs krönikörernas tankar om branschen
Nya tankegångar, åsikter och framtidsvisioner från profiler i branschen, tillika krönikörer i Life Science Sweden och vår systertidning Medtech Magazine. Här har vi samlat några av årets krönikor.
-
Tablet treatment for hair loss approved in the USA
The US Drug Administration has given a thumbs up for the first tablet treatment for spotty hair loss.
-
Bioventurehubs vd: ”Företag som interagerar mycket når större framgång”
Astra Zenecas Bioventurehub kan för första gången sedan starten rekrytera nya bolag då några av hyresgästerna växt väsentligt och nu lämnar hubben. Det berättar biohubbens vd Magnus Björsne i en intervju där han också lyfter fram en studie som pekar på att företag som interagerar mycket med andra bolag når större framgångar.
-
Collaboration for a simpler production of gene therapies launched
A collaboration between universities and companies aims at providing better production methods for the development of gene therapies. The initiative is led by Johan Rockberg, Professor at KTH.
BREAKING